Treatment of multicentric Castleman disease through combination of tocilizumab, lenalidomide and glucocorticoids: Case report.

Abstract:

RATIONALE:Castleman's disease (CD) is a rare lymphoproliferative disease. Compared to unicentric CD, multicentric Castleman disease (MCD) displays poorer prognosis and great variance to different therapies. Though chemotherapy, immunization therapy, and glucocorticoids have been used in the treatment of MCD, its optimal treatment is still controversial. PATIENT CONCERNS:A 47-year-old woman was admitted due to poor appetite, general fatigue, puffiness of face, systemic rash, and abdominal distension. On physical examination, the patient displayed as general lymphadenopathy, splenomegaly, hepatomegaly, and shifting dullness. DIAGNOSES:After biopsy of her swollen lymph node and laboratory tests, her initial diagnosis was hyaline vascular-CD. INTERVENTIONS:She was treated with combination of tocilizumab, lenalidomide, and glucocorticoids. OUTCOMES:This patient achieved complete remission (CR) with all her indexes returned to be normal. Her blood routines and biochemical examinations were still normal during the following period. LESSONS:We reported a case with multicentric Castleman's disease (MCD) which acquired quite good remission after combination treatment with tocilizumab, lenalidomide, and glucocorticoids. Our report provided powerful evidence for displaying the efficiency and safety of target therapy against unicentric Castleman disease.

journal_name

Medicine (Baltimore)

journal_title

Medicine

authors

Cai S,Zhong Z,Li X,Wang HX,Wang L,Zhang M

doi

10.1097/MD.0000000000017681

subject

Has Abstract

pub_date

2019-11-01 00:00:00

pages

e17681

issue

46

eissn

0025-7974

issn

1536-5964

pii

00005792-201911150-00012

journal_volume

98

pub_type

杂志文章

相关文献

MEDICINE文献大全